A Molecular Link Between Interleukin 22 and Intestinal Mucosal Wound Healing

Xiaoyan Sun,^{1,4} Laura Chalmers,¹⁻³ Xiaobing Fu,^{4,*} and Min Zhao^{1-3,**}

¹Departments of Dermatology and ²Ophthalmology, and ³Institute for Regenerative Cures, University of California Davis School of Medicine, Sacramento, California.

⁴Wound Healing and Cell Biology Laboratory, Institute of Basic Medical Science, Trauma Center of Postgraduate Medical School, Chinese PLA General Hospital, Beijing, People's Republic of China.

Background: Interleukin 22 (IL-22) and signal transducer and activator of transcription 3 (STAT3) are two important regulators of inflammation. Crohn's disease and ulcerative colitis are considered inflammatory bowel diseases (IBDs), due to the belief that these diseases result from dysregulated responses of the intestinal immune system to bacteria present in the commensal flora.

The Problem: It is debated whether a breakdown of immune tolerance is the primary cause of these diseases or occurs downstream of an initial defect of the intestinal barrier and intestinal epithelial cells (IECs).

Basic/Clinical Science Advances: Recent reports suggest a crucial role for IL-22 in the regulation of gut inflammation as well as epithelial barrier integrity. Local *IL-22* gene delivery enhances expression of its downstream effector, *STAT3*, within colonic epithelial cells and induces both *STAT3*-dependent expression of mucus-associated molecules and restitution of mucus-producing goblet cells. IEC-specific deletion of *STAT3* results in significant susceptibility to experimental colitis with a striking defect in epithelial restitution. *STAT3* activation, thus, may regulate immune homeostasis in the gut by promoting IL-22-dependent mucosal wound healing.

Clinical Care Relevance: The importance of IL-22/*STAT3* signaling in IEC wound healing suggests a critical role for epithelial homeostasis in IBDs.

Conclusion: Effective healing of the IECs could be considered a primary target in the development of treatments for IBDs. IL-22/*STAT3* signaling exerts a protective role in the process of intestinal mucosal wound healing and may thereby provide a promising therapeutic approach to the treatment of IBDs.

BACKGROUND

THE INTESTINAL EPITHELIUM provides the first line of immune defense against pathogens and a mechanism for processing food antigens. Defective healing of mucosa underlies many important intestinal diseases, including inflammatory bowel diseases (IBDs) such as Crohn's disease (CD) and ulcerative colitis. It is generally believed that dysregulation of the intestinal immune response and disruption of the intestinal epithelial

barrier are key features of IBDs. The respective contributions of the immunological pathways and/or the intestinal mucosal wound healing response have not yet been fully elucidated.

Recent reports have identified a crucial role for interleukin 22 (IL-22) in the regulation of both gut inflammation and epithelial barrier integrity. *IL-22* gene delivery leads to rapid amelioration of dextran sodium sulfate (DSS)-induced colitis,¹

Min Zhao

Submitted for publication August 8, 2011.

*Correspondence: Wound Healing and Cell Biology Laboratory, Institute of Basic Medical Science, Trauma Center of Postgraduate Medical School, Chinese PLA General Hospital, 28 Fu Xing Road, Beijing 100853, People's Republic of China (e-mail: fuxiaobing@vip.sina.com).

**Correspondence: Institute for Regenerative Cures, University of California Davis School of Medicine, 2921 Stockton Blvd., Room 1617, Sacramento, CA 95817 (e-mail: minzhao@ucdavis.edu).

Abbreviations and Acronyms

CD = Crohn's disease

CECs = colonic epithelial cells

DSS = dextran sodium sulfate

IL = interleukin

IBDs = inflammatory bowel diseases

IECs = intestinal epithelial cells

JAK kinases = Janus kinases

NK = natural killer

STAT3 = signal transducer and activator of transcription 3

Figure 1. The mucosal defense system: the intestinal epithelium lines the mucosal surface of the intestinal tract and is a key player in intestinal homeostasis. It provides the first line of immune defense against pathogens and a mechanism for proper processing of food antigens. Recent reports have identified a crucial role for IL-22/STAT3 signaling in the regulation of both gut inflammation and epithelial barrier integrity, which may provide a promising therapeutic approach to the treatment of IBDs, as well as other intestinal disorders (redrawn from Fig. 4 in Ref.²²). IL, interleukin; STAT3, signal transducer and activator of transcription 3. Color images available online at www.liebertpub.com/wound

TARGET ARTICLES

1. Pickert G, Neufert C, Leppkes M, Zheng Y, Wittkopf N, Warntjen M, *et al.*: STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. *J Exp Med* 2009; **206**: 1465.
2. Neufert C, Pickert G, Zheng Y, Wittkopf N, Warntjen M, Nikolaev A, Ouyang W, Neurath MF, and Becker C: Activation of epithelial STAT3 regulates intestinal homeostasis. *Cell Cycle* 2010; **9**: 652.

whereas *IL-22* knockout (*IL-22*^{-/-}) mice show increased intestinal epithelial damage, along with systemic bacterial burden and significantly increased mortality.² Sugimoto *et al.* demonstrated that *IL-22* local gene delivery enhanced signal transducer and activator of transcription 3 (STAT3) activation within colonic epithelial cells (CECs), and induced both STAT3-dependent expression of mucus-associated molecules and restitution of mucus-producing goblet cells.¹ Pickert *et al.* showed that intestinal epithelial STAT3 activation regulated immune homeostasis in the intestine by promoting IL-22-dependent mucosal wound healing.³ IL-22 and STAT3 are two important mediators of intestinal mucosal inflammation and wound healing (Fig. 1), and as such, we will focus on the roles of these two important immune signaling molecules in mucosal epithelial wound healing.

CLINICAL PROBLEM ADDRESSED

IBDs such as CD and ulcerative colitis are considered two of the most prevalent gastrointestinal diseases, and are lifelong diseases occurring early in life. The incidence of IBDs has markedly increased in recent years. The cellular/molecular mechanisms of IBDs have not yet been clarified, and immunosuppressive agents that nonspecifically reduce inflammation and immunity have been used as the mainstay treatments for IBDs. Evidence indicates that a dysregulation of mucosal immunity in the gut of IBD causes an overproduction of inflammatory cytokines and trafficking of effector leukocytes into the bowel, thus leading to an uncontrolled intestinal inflammation.⁴ Whether a breakdown of immune tolerance is the primary cause of these diseases or occurs downstream of an initial defect in the IECs/intestinal epithelial barrier is not yet clear.

RELEVANT BASIC SCIENCE CONTEXT

Recent research in the field of IBD has led to the identification of several cytokine pathways that may be potential therapeutic targets. One of these pathways comprises IL-22, a less well-defined cytokine associated with mucosal immune disorders. IL-22 was initially known as IL-10-related T-cell-derived inducible factor.⁵ Studies have revealed that IL-22 targets cells of the digestive, skin, and respiratory organ systems, thereby mediating epithelial innate immunity.⁶⁻⁸ IL-22 is produced by a subgroup of IL-17-producing CD4⁺ T-cells (Th17 cells).^{8,9} More recently, a unique IL-22 producing CD4⁺ T helper subset (Th22) has been identified in

psoriatic skin samples.⁷ Human Langerhans cells may differentiate T cells into the IL-22-producing T helper phenotype.¹⁰ Innate human immune cell types such as natural killer (NK) cells and lymphoid tissue inducer cells also produce IL-22.^{11,12} A distinct NK cell population (NKp46⁺) present in the mucosa-associated lymphoid tissue produces high levels of IL-22 and may be the main source of IL-22 in mucosal immunity.¹³ IL-22 can target epithelial cells instead of immune cells.^{9,14,15} IL-22, therefore, unlike other cytokines, has functions in epithelial cells as well as in inflammation.

The recent discovery that IL-22 activates STAT3 has improved our understanding of how IL-22 regulates intestinal epithelial wound healing in addition to its important role in the immune response. STAT3 has been identified as the key molecule involved in mediating the wound healing effect of IL-22. STAT3 is a transcription factor activated by a variety of cytokines and growth factors. On activation by Janus kinases (JAK kinases), STAT3 translocates to the nucleus, where it regulates expression of genes involved in apoptosis, proliferation, migration, and survival, depending on the cell type. It has been shown that high levels of phosphorylated STAT3, the active form, are present in both CD and ulcerative colitis, but not in healthy intestinal tissue.¹⁶

EXPERIMENTAL MODEL OR MATERIAL: ADVANTAGES AND LIMITATIONS

Experimental IBD was induced in the murine model in these studies. This is a well-used animal model for IBDs. The advantage of using this model is the highly detailed knowledge of its genetic makeup. Deletion of *STAT3* specifically in IECs has several advantages. Pickert *et al.* demonstrated the effects of STAT3 in epithelial cells, and excluded possible confounding involvement of the effects of STAT3 in immune cells. After removal of the colitis inducer DSS, wild-type animals with *STAT3* gene intact in intestinal epithelium recovered, whereas animals with *STAT3* gene knockout in IECs showed significantly delayed epithelial wound healing, epithelial erosion, and weight loss. These results clearly demonstrate the role of IL-22/STAT3 in IECs. IL-22 could promote wound healing through increased cell migration in IECs in wound assays.⁶ The protective role of IL-22 in IBD is likely to be linked to its functions in enhancing epithelial innate defense mechanisms and epithelial barrier integrity. IBDs result from complicated pathological processes, which include inflammatory responses, breaking down of the epithelial

barrier integrity, and it is possible that these two pathological processes may interact with and exacerbate each other. An initial breakdown of epithelial barrier integrity may severely impact the immune response. The contribution of each of these processes, however, is yet to be defined.

DISCUSSION OF FINDINGS AND RELEVANT LITERATURE

IL-22 signals through a class II cytokine receptor composed of two subunits, IL-22R1 and IL-10R2.⁹ IL-10R2 is widely expressed in immune cells (T, B, and NK cells), whereas IL-22R1 expression is present in a variety of nonimmune tissues, including skin, lung, small intestine, liver, colon, kidney, and pancreas.^{8,9} On binding to its heterodimeric receptor complex, IL-22R1 and IL-10R2, IL-22 activates the JAK1 and Tyk2 tyrosine kinases, thus leading to the phosphorylation of STAT3 and, to a lesser extent, of STAT1 and STAT5.^{8,9}

T cell-specific *STAT3* knockout mice showed impaired T cell proliferation.¹⁷ Activation of the *IL-6/STAT3* cascade in lamina propria T cells induced prolonged survival of pathogenic T cells and, indeed, inactivation of this cascade contributed to the attenuation of chronic intestinal inflammation.¹⁸ Disruption of innate immune responses may be brought about either by genetically engineered inactivation of the *STAT3* cascade in the CECs or by macrophage-induced intestinal inflammation.¹⁹ These results were confirmed in a subsequent study by using a conditional *STAT3* knockout mouse strain in which efficient deletion of STAT3 protein in innate cells (macrophages and CECs), but not acquired cells (T and B cells), caused development of a lethal colitis immediately in adults.²⁰

A novel microinjection-based local gene-delivery system allowed the targeting of inflamed mucosa and supplementation of local IL-22 expression restricted to the delivered site.¹ This method demonstrated the role of IL-22-mediated activation of the innate immune pathway in Th2-mediated colitis: *IL-22* gene delivery enhanced *STAT3* activation specifically within CECs and induced both *STAT3*-dependent expression of mucus-associated molecules and restitution of mucus-producing goblet cells.¹ Importantly, IL-22 contributed to the rapid amelioration of local intestinal inflammation by enhancing the production of membrane-bound mucins (Muc-1, -3, -10, and -13).¹ Membrane-bound mucins are stored in goblet cell vacuoles and form a static external barrier at the epithelial surface. Recent findings have indicated that Muc-2 and Muc-3 contribute to the suppression of experimental colitis. It is,

Figure 2. Schematic model of the regulation of intestinal homeostasis by the IL-22/STAT3 pathway in IECs. In the intestine, both innate and adaptive immune cells are capable of producing IL-22 in response to various stimuli. For instance, NKp46+ cells present in the mucosa-associated lymphoid tissue are the major innate source of IL-22. On binding to its heterodimeric receptor complex, IL-22R1 and IL-10R2, IL-22 activates the JAK1 and Tyk2 tyrosine kinases, thus leading to the phosphorylation of STAT3. The active STAT3 then translocates to the nucleus, where it regulates gene expression, which subsequently contributes to the suppression of intestinal inflammation, induces the expression of mucus-associated proteins and the restitution of mucus-producing goblet cells, and enhances the motility of IECs in the process of mucosal wound healing. NK, natural killer; JAK kinases, Janus kinases; IECs, intestinal epithelial cells. Color images available online at www.liebertpub.com/wound

therefore, possible that IL-22 stimulates mucus production and goblet cell restitution under intestinal inflammatory conditions and also contributes to the rapid attenuation of this inflammation. Consistent with these findings, Pickert *et al.* demonstrated a pivotal role for STAT3 activation in IECs for the restoration of the balance at the mucosal surface of the intestine in an experimental colitis model.³ By using genetically engineered mice with intestinal epithelial *STAT3* deletion, Pickert *et al.* defined IECs as important players in *STAT3*-dependent intestinal homeostasis and indicated that epithelial *STAT3* activation in DSS-induced colitis was dependent on IL-22, which was secreted by CD11c⁺ cells in response to Toll-like receptor stimulation.³ Activation of epithelial *STAT3* regulated genes associated with cellular stress, apoptosis, and wound repair, thus revealing an important role of *STAT3* in resolution of inflammation in the gut.³ To further test the role of IL-22 and *STAT3* signaling in human intestine, Neufert and colleagues extended their recent findings by showing that activation of *STAT3* also occurs in human IECs from patients with IBD.²¹ The authors stained colonic biopsies obtained from patients with CD with an antibody specific to phospho-*STAT3*, and found that samples from

patients with active CD showed elevated *STAT3* activity in the lamina propria as well as in IECs compared with controls.²¹ This result confirmed their findings using experimental colitis in mice in human tissues.³ Although the repetitive injection of a specific anti-IL-22 antibody every other day had little impact on the development of experimental colitis, antibody-mediated neutralization of IL-22 resulted in a significant delay in weight gain during the resolution phase, thus suggesting a protective role for IL-22 during resolution of experimental colitis.²¹

The protective roles of IL-22/*STAT3* in intestinal mucosal host defense may include the following: (1) IL-22 induces the proliferation and reconstitution of mucosal epithelial cells through the activation of *STAT3*, which enhances the healing response and prevents further penetration of microbes into the epithelial layer⁹; (2) IL-22 helps goblet cells to regenerate and produce mucus-associated proteins, which form the essential static external barrier separating intestinal flora from IECs⁹; (3) *STAT3* activation in IECs after induction of colitis or injury regulates the signaling pathways that are commonly involved in wound healing and which subsequently induce cell proliferation, remodeling of extracellular matrix and cell migration, and

contribute to the process of mucosal wound healing; and (4) IL-22 stimulates the production and secretion of various antimicrobial peptides, such as defensins, cathelicidins, and C-type lectins, from IECs and Paneth cells.⁹ These antimicrobial peptides further sequester and directly kill the invading pathogens through various mechanisms (Fig. 2).

INNOVATION

One innovative aspect of the target articles is to unmask the molecular cross-talk between the immune system and the intestinal epithelium. Based on the experimental data, the authors hypothesize a model in which a barrier defect within the intestinal epithelium facilitates the translocation of intestinal microbes into the submucosa where they encounter dendritic cells and other innate immune cells.^{1,3,21} On pattern recognition including activation of Toll-like receptors by innate immune cells, early defense mechanisms are activated that include the production of IL-22 by IL-22-producing innate cells (e.g., CD11c⁺ cells). Subsequently, IL-22 binds to the IL-22 receptor complex expressed by IECs that initiates a signaling cascade and results in the activation of STAT3 in IECs. STAT3 phosphorylation in IECs then promotes a transcriptional cascade which comprises the induction of targets that favor mucosal wound healing.^{1,3,21} Several mechanisms including proliferation, antiapoptosis, and production of antimicrobial proteins such as RegIII β and RegIII γ are thereby involved in restoration of intestinal homeostasis. Thus, targeting the IL-22/STAT3 signaling pathway in IECs is a promising therapeutic approach in situations where intestinal homeostasis is compromised, for example, CD, and ulcerative colitis.

CAUTION, CRITICAL REMARKS, AND RECOMMENDATIONS

Recent human- and experimental animal-based studies have highlighted the IL-22/STAT3 signaling pathway in IBDs. The activation of IL-22/STAT3 has a protective role in the intestinal epithelium through which cells of the innate immune responses regulate host defense, inflammation,

TAKE-HOME MESSAGE

Basic science advances

IL-22 is a central regulator of mucosal host defense, and is crucial for epithelial barrier integrity. IL-22 binds to its receptor complex, thereby resulting in the activation of STAT3 in IECs. Activation of STAT3 significantly enhances wound healing responses in IECs through the upregulation of many genes important to epithelial wound healing, stimulation of IEC proliferation and migration, reduction of epithelial erosion *in vivo*, and subsequent recovery of body weight after DSS-induced colitis in mice. The mucosal healing responses also include expression of mucus-associated proteins, the restitution of mucus-producing goblet cells, and enhancement of IEC motility. Recovery of the barrier should also contribute to the suppression of intestinal inflammation. Thus, the protective role of IL-22/STAT3 in intestinal mucosal host defense may include (1) inducing the proliferation and restitution of mucosal epithelial cells through the activation of STAT3; (2) helping goblet cell regeneration and production of mucus-associated proteins; (3) modulating the genes that are commonly involved in wound healing and induce cell proliferation, remodeling of extracellular matrix, and cell migration during mucosal wound healing; and (4) stimulating secretion of antimicrobial peptides. The IL-22/STAT3 signaling involved in intestinal homeostasis sheds new light on the molecular mechanisms underlying the mucosal wound healing process.

Clinical science advances

Animal experiments have identified the molecular basis of IL-22/STAT3 signaling in IBDs, and found similarities to pathogenic functions in chronic inflammatory skin diseases. In IBDs, IL-22/STAT3 signaling plays an essential role in epithelial wound healing. Further investigation of the mechanisms of IL-22/STAT3 signaling in psoriasis and IBDs will yield significant insights into epithelial wound healing and inflammatory responses. Elucidating these conflicting effects will aid in the design of therapeutic treatments targeting the IL-22/STAT3 pathway for the treatment of IBDs.

Relevance to clinical care

Importantly, healing of the epithelium and recovery of the barrier function has significant effects in improving the overall health of the organism, including mucosal erosion and body weight recovery. These are important parameters that clinicians aim at improving. Healing of the epithelium may have an equally important role in the management of IBDs.

However, the protective role of IL-22/STAT3 signaling in IBD marks an important first step in linking the immune system to the intestinal epithelium. Future studies should focus on defining the context-dependent functions of IL-22/STAT3 signaling in intestinal inflammation and repair, including the effect of microbial communities at epithelial barrier surfaces, and the spatial and temporal co-expression of other proinflammatory or regulatory cytokines. In addition, the role of IL-22/STAT3 signaling during tumorigenesis should be addressed, to develop therapeutic approaches that will target intestinal mucosal wound healing while avoiding tumor development or exacerbation.

and tissue homeostasis at epithelial barrier surfaces. Accordingly, targeting the IL-22/STAT3 signaling pathway may be a promising therapeutic approach for patients with intestinal disorders such as CD and ulcerative colitis.

Development, plasticity, and cell-lineage relationships of innate sources of IL-22 in mouse and human diseases remain unclear. Further examination

pin-pointing the role of different IL-22-expressing subsets is needed to underline the regulatory network of cytokine expression in immunity and homeostasis of the intestinal tract. In addition, the IL-22/STAT3 signaling pathway plays a protective role in the regulation of intestinal inflammation, enhances wound repair, and is crucial for epithelial barrier integrity. Unfortunately, similar to many cytokines that hold dual roles, IL-22 plays an essential role in the pathogenesis of psoriasis.^{7,9,14} IL-22 can synergize with other proinflammatory cytokines to induce many of the pathogenic phenotypes of keratinocytes and exacerbate disease progression.^{7,9,14} Further investigation aimed at elucidating these apparently conflicting effects will aid in the design of therapeutic treatments targeting the IL-22/STAT3 pathway for the treatment of persistent infections, chronic inflammation, and autoimmune diseases. Finally, current studies have revealed the roles of IL-22/STAT3 signaling in aiding tissue repair.^{1,3,14,21,22} In particular, IL-22 is constitutively expressed by CD11c⁺ cells within the small intestine, a tissue that undergoes constant renewal and is susceptible to tumorigenesis. It is, therefore, critical to devise an elaborate regulatory method to keep IL-22/STAT3 signaling under control to promote mucosal wound healing during inflammation while avoiding tumorigenesis, because STAT3 activation may be related to tumor formation.

FUTURE DEVELOPMENT OF INTEREST

Future studies will focus on defining the context-dependent functions of IL-22/STAT3 signaling in

tissue inflammation and repair, including the effect of microbial communities at the epithelial barrier surface and the spatial and temporal co-expression of other proinflammatory or regulatory cytokines. In addition to the role of IL-22/STAT3 signaling under inflammatory conditions, the role of this signaling pathway in tumorigenesis needs to be more closely examined. Better understanding is important for development of therapeutic treatments targeting the IL-22/STAT3 pathway for the treatment of intestinal mucosal disorders, which block potential tumorigenic side-effects during the mucosal wound-healing process, but leave the protective functions of IL-22 intact.

ACKNOWLEDGMENTS AND FUNDING SOURCES

Research in the author's lab is supported by grants from NIH (1R01EY019101), California Institute of Regenerative Medicine (RB1-01417), NSF (MCB-0951199), Research to Prevent Blindness, Inc., NSFC (30901564, 30730090, 81121004), and the National Basic Science and Development Programme (973 Programme, 2012CB518105). The author (MZ) served as an *ad hoc* consultant for Johnson & Johnson.

AUTHOR DISCLOSURE AND GHOSTWRITING

The authors declare no conflict of interest. This article was not written by any writer other than the authors.

REFERENCES

1. Sugimoto K, Ogawa A, Mizoguchi E, Shimomura Y, Andoh A, Bhan AK, Blumberg RS, Xavier RJ, and Mizoguchi A: IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. *J Clin Invest* 2008; **118**: 534.
2. Zheng Y, Valdez PA, Danilenko DM, Hu Y, Sa SM, Gong Q, Abbas AR, Modrusan Z, Ghilardi N, de Sauvage FJ, and Ouyang W: Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. *Nat Med* 2008; **14**: 282.
3. Pickert G, Neufert C, Leppkes M, Zheng Y, Wittkopf N, Warntjen M, Lehr HA, Hirth S, Weigmann B, Wirtz S, Ouyang W, Neurath MF, and Becker C: STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. *J Exp Med* 2009; **206**: 1465.
4. Strober W, Fuss I, and Mannon P: The fundamental basis of inflammatory bowel disease. *J Clin Invest* 2007; **117**: 514.
5. Dumoutier L, Louahed J, and Renauld JC: Cloning and characterization of IL-10-related T cell-derived inducible factor (IL-TIF), a novel cytokine structurally related to IL-10 and inducible by IL-9. *J Immunol* 2000; **164**: 1814.
6. Aujla SJ and Kolls JK: IL-22: a critical mediator in mucosal host defense. *J Mol Med* 2009; **87**: 451.
7. Eyerich S, Eyerich K, Pennino D, Carbone T, Nasorri F, Pallotta S, Cianfrani F, Odorisio T, Traidl-Hoffmann C, Behrendt H, Durham SR, Schmidt-Weber CB, and Cavani A: Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. *J Clin Invest* 2009; **119**: 3573.
8. Wolk K, Witte E, Witte K, Warszawska K, and Sabat R: Biology of interleukin-22. *Semin Immunopathol* 2010; **32**: 17.
9. Ouyang W: Distinct roles of IL-22 in human psoriasis and inflammatory bowel disease. *Cytokine Growth Factor Rev* 2010; **21**: 435.
10. Fujita H, Nogales KE, Kikuchi T, Gonzalez J, Carucci JA, and Krueger JG: Human Langerhans cells induce distinct IL-22-producing CD4⁺ T cells lacking IL-17 production. *Proc Natl Acad Sci USA* 2009; **106**: 21795.
11. Colonna M: Interleukin-22-producing natural killer cells and lymphoid tissue inducer-like cells in mucosal immunity. *Immunity* 2009; **31**: 15.
12. Spits H and Di Santo JP: The expanding family of innate lymphoid cells: regulators and effectors of

- immunity and tissue remodeling. *Nat Immunol* 2011; **12**: 21.
13. Cella M, Fuchs A, Vermi W, Facchetti F, Otero K, Lennerz JK, Doherty JM, Mills JC, and Colonna M: A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. *Nature* 2009; **457**: 722.
 14. Boniface K, Bernard FX, Garcia M, Gurney AL, Lecron JC, and Morel F: IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. *J Immunol* 2005; **174**: 3695.
 15. Sa SM, Valdez PA, Wu J, Jung K, Zhong F, Hall L, Kasman I, Winer J, Modrusan Z, Danilenko DM, and Ouyang W: The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. *J Immunol* 2007; **178**: 2229.
 16. Lovato P, Brender C, Agnholt J, Kelsen J, Kaltoft K, Svejgaard A, Eriksen KW, Woetmann A, and Ødum N: Constitutive STAT3 activation in intestinal T cells from patients with Crohn's disease. *J Biol Chem* 2003; **278**: 16777.
 17. Takeda K, Kaisho T, Yoshida N, Takeda J, Kishimoto T, and Akira S: Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specific Stat3-deficient mice. *J Immunol* 1998; **161**: 4652.
 18. Atreya R, Mudter J, Finotto S, Müllberg J, Jostock T, Wirtz S, Schütz M, Bartsch B, Holtmann M, Becker C, Strand D, Czaja J, Schlaak JF, Lehr HA, Autschbach F, Schürmann G, Nishimoto N, Yoshizaki K, Ito H, Kishimoto T, Galle PR, Rose-John S, and Neurath MF: Blockade of interleukin 6 trans-signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn's disease and experimental colitis *in vivo*. *Nat Med* 2000; **6**: 583.
 19. Welte T, Zhang SS, Wang T, Zhang Z, Hesslein DG, Yin Z, Kano A, Iwamoto Y, Li E, Craft JE, Bothwell AL, Fikrig E, Koni PA, Flavell RA, and Fu XY: STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: a critical role of STAT3 in innate immunity. *Proc Natl Acad Sci USA* 2003; **100**: 1879.
 20. Alonzi T, Newton IP, Bryce PJ, Di Carlo E, Latanzio G, Tripodi M, Musiani P, and Poli V: Induced somatic inactivation of STAT3 in mice triggers the development of a fulminant form of enterocolitis. *Cytokine* 2004; **26**: 45.
 21. Neufert C, Pickert G, Zheng Y, Wittkopf N, Warntjen M, Nikolaev A, Ouyang W, Neurath MF, and Becker C: Activation of epithelial STAT3 regulates intestinal homeostasis. *Cell Cycle* 2010; **9**: 652.
 22. Li Z, Burns AR, Byeseda Miller S, and Smith CW: CCL20, $\gamma\delta$ T cells, and IL-22 in corneal epithelial healing. *FASEB J* 2011; **25**: 2659.